Prosecution Insights
Last updated: May 29, 2026

Lantern Pharma Inc.

7 pending office actions • 7 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready

Portfolio Summary

7
Total Pending OAs
4
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

4
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (4)Due ≤ 30 days (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (57%)
1
Easy (14%)
2
Unknown (29%)

Rejection Statute Mix

BucketCases
§103 only4 (57%)
§112 only1 (14%)
No statute on record2 (29%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

7
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

70 h
Manual time on pending OAs
14 h
Time saved (low, 20%)
24 h
Time saved (mid, 35%)
0.6 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BARSKY, JARED 1 50.2% +23.0%
BONAPARTE, AMY C 1 79.8% +23.1%
BRAUN, MADELINE E 1 68.0% +24.9%
MAHLUM, JONATHAN DAVIS 1 57.7% +6.9%
WILSON, JERICA KATLYNN 1 60.6% +40.0%
CHOUDHURY, NURA MANSURA 1 100.0% +0.0%
VISONE, THOMAS J 1 54.4% +41.4%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17811812 Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate CHOUDHURY, NURA MANSURA 77d

Interview Candidates (5)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.

App #TitleExaminerDue in
18349256 TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE BRAUN, MADELINE E 89d overdue
18500032 Method for Treating Blood Cancers BARSKY, JARED 49d overdue
17230821 Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers VISONE, THOMAS J 37d overdue
18238512 ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME BONAPARTE, AMY C 2d overdue
17995904 Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer WILSON, JERICA KATLYNN 14d

Top Art Units

Art UnitApps
1628 1
1692 1
1624 1
1625 1
1621 1
1683 1
1672 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18500032 Method for Treating Blood Cancers BARSKY, JARED 1628 §103 Non-Final OA 49d overdue Pending Nov 01, 2023
18238512 ILLUDIN ANALOGS, USES THEREOF, AND METHODS FOR SYNTHESIZING THE SAME BONAPARTE, AMY C 1692 §112 Non-Final OA 2d overdue Pending Aug 27, 2023
18349256 TREATMENT OF BRAIN METASTASES AND CNS METASTASES USING ILLUDINS OR HYDROXYLUREAMETHYL ACYLFULVENE BRAUN, MADELINE E 1624 Other Non-Final OA 89d overdue Pending Jul 10, 2023
17998117 Method For Treating Pancreatic Cancer MAHLUM, JONATHAN DAVIS 1625 §103 Non-Final OA 26d Pending Nov 07, 2022
17995904 Hydroxyureamethyl-Acylfulvene for Treating Brain Cancer or CNS Cancer WILSON, JERICA KATLYNN 1621 §103 Final Rejection 14d Pending Oct 10, 2022
17811812 Method for Determining Sensitivity to 2,2'-Dithio-bis-Ethane Sulfonate CHOUDHURY, NURA MANSURA 1683 §103 Final Rejection 77d Pending Jul 11, 2022
17230821 Methods for the Treatment of Solid Tumor Cancers Using Illudins and Biomarkers VISONE, THOMAS J 1672 Other Final Rejection 37d overdue Pending Apr 14, 2021

Managing Lantern Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month